JP7086008B2 - ガレクチンに関連する疾患を予防および処置するためのセレノガラクトシド化合物およびその使用 - Google Patents

ガレクチンに関連する疾患を予防および処置するためのセレノガラクトシド化合物およびその使用 Download PDF

Info

Publication number
JP7086008B2
JP7086008B2 JP2018566189A JP2018566189A JP7086008B2 JP 7086008 B2 JP7086008 B2 JP 7086008B2 JP 2018566189 A JP2018566189 A JP 2018566189A JP 2018566189 A JP2018566189 A JP 2018566189A JP 7086008 B2 JP7086008 B2 JP 7086008B2
Authority
JP
Japan
Prior art keywords
group
galectin
substituted
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018566189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507194A5 (enExample
JP2019507194A (ja
Inventor
シャーロン・シェクター
エリーザー・ゾマー
ピーター・ジー・トレーバー
ラファエル・ニール
ジョセフ・エム・ジョンソン
ライアン・ジョージ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galectin Sciences LLC
Original Assignee
Galectin Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Sciences LLC filed Critical Galectin Sciences LLC
Publication of JP2019507194A publication Critical patent/JP2019507194A/ja
Publication of JP2019507194A5 publication Critical patent/JP2019507194A5/ja
Application granted granted Critical
Publication of JP7086008B2 publication Critical patent/JP7086008B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2018566189A 2016-03-04 2017-03-03 ガレクチンに関連する疾患を予防および処置するためのセレノガラクトシド化合物およびその使用 Active JP7086008B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662303872P 2016-03-04 2016-03-04
US62/303,872 2016-03-04
PCT/US2017/020658 WO2017152048A1 (en) 2016-03-04 2017-03-03 Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof

Publications (3)

Publication Number Publication Date
JP2019507194A JP2019507194A (ja) 2019-03-14
JP2019507194A5 JP2019507194A5 (enExample) 2020-04-09
JP7086008B2 true JP7086008B2 (ja) 2022-06-17

Family

ID=59744474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018566189A Active JP7086008B2 (ja) 2016-03-04 2017-03-03 ガレクチンに関連する疾患を予防および処置するためのセレノガラクトシド化合物およびその使用

Country Status (11)

Country Link
US (2) US20190367552A1 (enExample)
EP (1) EP3423461A4 (enExample)
JP (1) JP7086008B2 (enExample)
KR (1) KR102346913B1 (enExample)
CN (1) CN109071585B (enExample)
AU (1) AU2017228365B2 (enExample)
CA (1) CA3016343C (enExample)
IL (2) IL261431B (enExample)
MX (1) MX394409B (enExample)
WO (1) WO2017152048A1 (enExample)
ZA (1) ZA201805900B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102626669B1 (ko) * 2017-05-12 2024-01-17 갈랙틴 사이언시즈, 엘엘씨 질환의 예방 및 치료를 위한 화합물 및 이의 용도
JP2021501180A (ja) * 2017-10-31 2021-01-14 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用
KR20210124308A (ko) * 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
US12404295B2 (en) * 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
CN113476442A (zh) * 2021-07-28 2021-10-08 上海交通大学医学院附属第九人民医院 化合物gb-0139在治疗心肌梗死后心肌过度纤维化的药物中的应用
KR102990426B1 (ko) 2022-04-06 2026-07-13 (주)샤페론 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 폐섬유증 예방 또는 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510223A (ja) 2006-11-15 2010-04-02 サ ブリガム アンド ウィメンズ ホスピタル インコーポレーティッド Ｔｉｍ−３調節物質の治療的使用
WO2014078655A1 (en) 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
JP2015503658A (ja) 2011-12-28 2015-02-02 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ヒト疾患処置用の新規糖薬剤の組成物
WO2015155207A1 (en) 2014-04-08 2015-10-15 Galecto Biotech Ab Galactoside inhibitors for the treatment of alpha-synucleinopthies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401301D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
ES2652488T3 (es) * 2009-04-28 2018-02-02 Galecto Biotech Ab Nuevos inhibidores de galactósidos de galectinas
CA2794066C (en) * 2012-10-31 2017-02-28 Neil Henderson Galactoside inhibitor of galectins
CA2848711C (en) * 2011-09-16 2019-08-06 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
EP2620443A1 (en) * 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
IN2015DN02573A (enExample) * 2012-10-31 2015-09-11 Galecto Biotech Ab
EP3125908A4 (en) * 2014-03-10 2017-11-15 La Jolla Pharmaceutical Company Compositions and methods for treating kidney disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510223A (ja) 2006-11-15 2010-04-02 サ ブリガム アンド ウィメンズ ホスピタル インコーポレーティッド Ｔｉｍ−３調節物質の治療的使用
JP2015503658A (ja) 2011-12-28 2015-02-02 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ヒト疾患処置用の新規糖薬剤の組成物
WO2014078655A1 (en) 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
WO2015155207A1 (en) 2014-04-08 2015-10-15 Galecto Biotech Ab Galactoside inhibitors for the treatment of alpha-synucleinopthies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Carbohydrate Research，2012年，360，p.8-18

Also Published As

Publication number Publication date
US20190367552A1 (en) 2019-12-05
BR112018067693A2 (pt) 2019-01-08
CN109071585A (zh) 2018-12-21
CA3016343A1 (en) 2017-09-08
KR102346913B1 (ko) 2022-01-04
MX394409B (es) 2025-03-24
JP2019507194A (ja) 2019-03-14
EP3423461A4 (en) 2020-03-25
WO2017152048A1 (en) 2017-09-08
KR20180128419A (ko) 2018-12-03
CA3016343C (en) 2024-03-26
MX2018010683A (es) 2019-05-27
AU2017228365B2 (en) 2021-05-27
ZA201805900B (en) 2019-07-31
AU2017228365A1 (en) 2018-09-27
IL281585B (en) 2022-04-01
US20230127345A1 (en) 2023-04-27
IL281585A (en) 2021-05-31
EP3423461A1 (en) 2019-01-09
CN109071585B (zh) 2022-08-16
IL261431A (en) 2018-10-31
IL261431B (en) 2021-04-29

Similar Documents

Publication Publication Date Title
CN110869378B (zh) 预防和治疗疾病的化合物及其用途
US20230127345A1 (en) Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
WO2019089080A9 (en) Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
JP2022524678A (ja) ガレクチンのα－Ｄ－ガラクトシド阻害剤
CN111032670A (zh) 用于治疗系统性胰岛素抗性病症的化合物及其用途
KR102692840B1 (ko) 의학적 장애의 예방 및 치료를 위한 화합물 및 이의 용도
JP2020122021A (ja) ガレクチンの新規なガラクトシド阻害剤
BR112018067693B1 (pt) Selenogalactosídeos, seus usos, e composição

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210521

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220228

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220317

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220607

R150 Certificate of patent or registration of utility model

Ref document number: 7086008

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250